Absorbable interference screw
By using absorbable interface screws made of composite materials composed of degradable polymers, polyethylene glycol, hydroxyapatite and maleic anhydride, the problem of mismatch between the mechanical strength and the degradation speed in the prior art is solved. , achieving stable mechanical properties and controllable biodegradability, improving its safety and application range in ACL reconstruction.
Patent Information
- Application Number
- CN202411245207.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-06
AI Technical Summary
The existing absorbable interface screws have disadvantages such as poor mechanical strength, foreign body reaction, degradation and absorption speed and bone tunnel healing, which affect their stability and safety.
The biodegradable polymer composite material consisting of 65 to 80 parts by weight of degradable polymer polymer, 5 to 15 parts by weight of polyethylene glycol, 15 to 25 parts by weight of hydroxyapatite and a certain proportion of maleic anhydride, is adopted. The injection molding process produces absorbable interface screws to control their mechanical properties and biodegradable properties.
The designed absorbable interface screw has stable mechanical properties and controllable biodegradable properties. It can maintain good mechanical properties during the bone tunnel healing period, reduce the risk of ligament loosening, and has a high cost advantage, making it suitable for clinical applications.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medical devices, and in particular to an absorbable interface screw. Background Art
[0002] In recent years, with the accelerated pace of social life and the improvement of living standards, sports and fitness have become an indispensable part of people's lives. The number of sports-related diseases has also been increasing, and the most common is anterior cruciate ligament (ACL) injury of the knee. Due to the poor regeneration ability of ACL injury, if it is not treated early, it may cause a series of complications such as cartilage and meniscus injury, osteoarthritis, knee joint laxity, etc., resulting in knee instability and cartilage degeneration, thus affecting the patient's quality of life.
[0003] At present, the most recognized and effective clinical solution for the treatment of ACL injury is to use an interface screw to directly squeeze and fix the ligament graft in the bone tunnel of the articular surface to reconstruct the ligament, that is, ACL reconstruction surgery. During ACL reconstruction, the choice of fixation method is an important issue faced during the operation. At present, metal interface screws are widely used in the clinic to apply pressure to the cancellous bone in the bone tunnel to complete the fixation of the bone-patellar tendon-graft to promote early tendon-bone healing. However, metal interface screws have the disadvantages of modulus mismatch with ligament site and need for secondary surgery to remove. Compared with metal interface screws, absorbable interface screws have no metal residue in the body and do not require secondary surgery to remove. They do not affect postoperative MRI examinations, nor do they cause difficulties for revision surgery. In addition, gaps appear as they degrade and absorb, which facilitates the creeping replacement of cancellous bone and can further increase their stability. In view of the role and advantages of absorbable interface screws in sports trauma repair, more than ten years ago, large foreign manufacturers of sports medicine implants launched absorbable interface screw products.
[0004] In addition, although PLLA-HA composite interface screws have good biocompatibility and are endowed with bone conductivity and biodegradability, clinical practice has found that such screws still have obvious disadvantages such as poor mechanical strength, foreign body reaction, and mismatch between degradation and absorption rate and bone tunnel healing. The main reasons are: (1) Nano-HA has a high surface energy, which will cause serious agglomeration in the PLLA matrix, resulting in unstable mechanical properties of the product; (2) The difference in physical and chemical properties between HA powder and PLLA matrix causes a weak interface between the two. During the degradation process, HA powder is easy to fall off from the PLLA matrix, causing premature failure of the composite material; (3) The solubility of HA under physiological conditions is extremely low, especially dense HA will show a lower biodegradation rate. If the degradation time of the composite material is too long, complications such as delayed foreign body reaction may occur.
[0005] Therefore, it is of great significance to develop an absorbable interference screw with good biocompatibility, stable mechanical properties and controllable degradation rate. Summary of the invention
[0006] In view of the above-mentioned technical defects of absorbable interface screws in the prior art, the present invention aims to provide a more cost-effective absorbable interface screw with good biocompatibility, stable mechanical properties, and controllable degradation rate to ensure good mechanical property retention during the bone tunnel healing period, so as to achieve independent innovation and industrial application of absorbable interface screws.
[0007] To achieve the above object, the present invention adopts the following technical solution:
[0008] An absorbable interface screw is prepared by an injection molding process of a biodegradable polymer composite material consisting of 65-80 parts by weight of a degradable high molecular polymer, 5-15 parts by weight of polyethylene glycol, 15-25 parts by weight of hydroxyapatite and a certain proportion of maleic anhydride, wherein the injection molding temperature is 200-240°C, the injection pressure is 200-300 bar, and the holding time is 30-120 seconds; the degradable high molecular polymer is a composite of polylactic acid and polylactic acid-glycolic acid copolymer in a weight ratio of 1:(4-9); the hydroxyapatite is hydroxyapatite powder with an average particle size of 800 nm-10 μm or hydroxyapatite whisker with a diameter of 50-500 nm and an aspect ratio of 10-40; and the amount of maleic anhydride in the biodegradable polymer composite material is 1-3% of the total weight of the degradable high molecular polymer, polyethylene glycol and hydroxyapatite.
[0009] The viscosity-average molecular weight of the polylactic acid is 100,000 to 200,000, and is selected from at least one of left-handed polylactic acid (PLLA), racemic polylactic acid (PDLLA), a blend of right-handed polylactic acid and left-handed polylactic acid (PDLA / PLLA), and a blend of racemic polylactic acid and left-handed polylactic acid (PDLLA / PLLA), preferably left-handed polylactic acid or a blend of left-handed polylactic acid and racemic polylactic acid.
[0010] The molar content of the lactide monomer in the polylactic acid-glycolic acid copolymer is 50-85%, and the molar content of the glycolide monomer is 15-50%; the viscosity average molecular weight of the polylactic acid-glycolic acid copolymer is 200,000-600,000.
[0011] The viscosity average molecular weight of the polyethylene glycol is 200-10000, preferably 400-8000, more preferably 1000-2000.
[0012] As an improvement of the above technical solution, the interface screw is made of a biodegradable polymer composite material composed of 70 to 75 parts by weight of a degradable high molecular polymer, 7 to 12 parts by weight of polyethylene glycol, 15 to 20 parts by weight of hydroxyapatite and a certain proportion of maleic anhydride through an injection molding process; the polylactic acid in the degradable high molecular polymer is a left-handed polylactic acid with a viscosity-average molecular weight of 100,000 to 150,000; the molar ratio of the monomer lactide to the monomer glycolide in the polylactic acid-glycolic acid copolymer is 50:50 or 65:35, and the viscosity-average molecular weight of the polylactic acid-glycolic acid copolymer is 300,000 to 400,000.
[0013] Preferably, the weight ratio of polylactic acid to polylactic acid-glycolic acid copolymer in the degradable high molecular polymer is 1:(4-6); and the hydroxyapatite is hydroxyapatite powder with an average particle size of 1-5 μm.
[0014] As another improvement of the above technical solution, the interface screw is made of a biodegradable polymer composite material composed of 70 to 75 parts by weight of a degradable high molecular polymer, 5 to 10 parts by weight of polyethylene glycol, 20 to 25 parts by weight of hydroxyapatite and a certain proportion of maleic anhydride through an injection molding process; the polylactic acid in the degradable high molecular polymer is a blend of left-handed polylactic acid and racemic polylactic acid with a viscosity-average molecular weight of 100,000 to 150,000, the molar ratio of the monomer lactide to the monomer glycolide in the polylactic acid-glycolic acid copolymer is 75:25 or 85:15, and the viscosity-average molecular weight of the polylactic acid-glycolic acid copolymer is 200,000 to 350,000.
[0015] Preferably, the weight ratio of polylactic acid to polylactic acid-glycolic acid copolymer in the degradable high molecular polymer is 1:(7-9); and the hydroxyapatite is a hydroxyapatite whisker with an aspect ratio of 20-40.
[0016] Preferably, the weight ratio of L-polylactic acid to racemic polylactic acid in the blend of L-polylactic acid and racemic polylactic acid is 50-65:35-50.
[0017] Preferably, the biodegradable polymer composite material in the above technical solution is prepared by melt blending in a twin-screw extruder, the melt blending temperature is 180-230° C., and the screw speed of the twin-screw extruder is 150-250 rpm.
[0018] The beneficial effects of the present invention are:
[0019] 1. A new polylactic acid / PLGA composite matrix system for injection molding absorbable interface screws was designed by selecting the polylactic acid component, regulating the dosage ratio of the polylactic acid component and the PLGA component, and regulating the ratio between the monomer lactide and the monomer glycolide in the PLGA structure. Micro-nano hydroxyapatite of a specific size was introduced as a filler to endow the interface screws with stable mechanical properties and controllable biodegradability. This can effectively avoid the risks of loosening of the ligament due to the expansion of the bone tunnel caused by the rapid biodegradation rate of the interface screw, or the risks of continuous low-level inflammatory response complications caused by the slow degradation time, which is not conducive to the ingrowth of bone tissue and poor support for the formation of new tissues, thereby greatly improving the safety of clinical use of absorbable interface screws.
[0020] 2. The present invention uses hydroxyapatite powder or whiskers with larger particle size instead of nano-hydroxyapatite powder commonly used in the prior art as a filler, which not only gives the interface screw good osteoinductive properties, but also avoids the defect of unstable initial mechanical properties of the interface screw product caused by the easy agglomeration of nano-hydroxyapatite powder in the polymer matrix, and the axial pull-out force of the absorbable interface screws between different batches fluctuates less; the initial axial pull-out force of the interface screw with hydroxyapatite powder as a filler can be stabilized at 1000~1200N, and the axial pull-out force can be maintained in the range of 650~750N after 24 weeks of in vitro degradation, which is 5 times higher than the maximum load value of ACL reconstruction rehabilitation period verified by clinical studies 00N; the initial axial pull-out force of the interface screw with hydroxyapatite whiskers as filler can be stabilized at 1200~1350N, and the axial pull-out force can be maintained at more than 850N after 24 weeks of in vitro degradation; and the axial pull-out force retention rate of the absorbable interface screw provided by the present invention can still be maintained at more than 50% after 32 weeks of in vitro degradation, which can not only meet the exercise needs of patients in the rehabilitation period of ACL reconstruction under normal bone (the bone tunnel healing period is about 26 weeks), but also meet the exercise needs of middle-aged and elderly patients whose bone tunnel healing period is longer due to osteoporosis or young patients whose bone tunnel healing period is prolonged due to other reasons, further broadening the clinical application scope of absorbable interface screws.
[0021] 3. The biodegradable matrix materials used in the absorbable interface screws of the present invention are all conventional raw materials that are easily available and reasonably priced on the market, and have greater cost advantages compared to foreign competing products. DETAILED DESCRIPTION
[0022] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.
[0023] In the following examples and comparative examples, the experimental methods used are conventional methods unless otherwise specified, and the reagents or instruments used without indicating the manufacturer are conventional products that can be purchased commercially.
[0024] The polymer matrix materials used in the examples and comparative examples of the present invention are commercially available, but are not limited to these materials:
[0025] Poly (L-lactic acid) (PLLA): purchased from Shenzhen Jusheng Biotechnology Co., Ltd., with a viscosity-average molecular weight of 100,000 to 150,000;
[0026] Racemic polylactic acid (PDLLA): purchased from Wuhan Haishan Technology Co., Ltd., with a viscosity-average molecular weight of 150,000 to 200,000;
[0027] PLGA (50:50): purchased from Shenzhen Jusheng Biotechnology Co., Ltd., with a viscosity-average molecular weight of 250,000 to 300,000;
[0028] PLGA (65:35): purchased from Xi'an Ruixi Biotechnology Co., Ltd., with a viscosity-average molecular weight of 300,000 to 350,000;
[0029] PLGA (75:25): purchased from Shenzhen Boli Biomaterials Co., Ltd., with a viscosity-average molecular weight of 350,000 to 400,000;
[0030] PLGA (85:25): purchased from Shanghai Sai Ke Rui Biotechnology Co., Ltd., with a viscosity-average molecular weight of 200,000-250,000.
[0031] The preparation methods of absorbable interface screws of Examples 1 to 18 of the present invention and Comparative Examples 1 to 5 are as follows:
[0032] S1: According to the weight ratio of Table 1, Table 2 and Table 3, weigh each component and put it into a high-speed mixer and premix it at a speed of 400 r / min for 5 minutes to obtain a premix;
[0033] S2: putting the premix of step S1 into a twin-screw extruder for melt blending and extrusion granulation, and drying at 80° C. to obtain a biodegradable polymer composite material for preparing an absorbable interface screw.
[0034] The processing temperature of each section of the twin-screw extruder is: 180°C in zone 1, 190°C in zone 2, 220°C in zone 3, 222°C in zone 4, 224°C in zone 5, 226°C in zone 6, 230°C in zone 7, 230°C in zone 8, and 220°C in zone 9; the screw speed of the twin-screw extruder is 200r / min.
[0035] S3: putting the biodegradable polymer composite material of step S2 into the material trough of the injection molding machine, injecting the molten composite granules into the mold of the desired screw shape through the screw, and then cooling and demolding to obtain the interface screw.
[0036] The injection molding temperature is 200-240°C, specifically 200°C, 210°C, 220°C, 230°C or 240°C, and is 210°C in the embodiment of the present invention; the injection pressure is 200-300bar, specifically 200bar, 220bar, 240bar, 260bar, 280bar or 300bar, and is 240bar in the embodiment of the present invention; the holding time is 30-120s, specifically 30s, 40s, 50s, 60s, 70s, 80s, 90s, 100s, 110s or 50s, and is 40s in the embodiment of the present invention; the mold temperature of the injection molding is 30-45°C, specifically 30°C, 35°C, 40°C or 45°C, and is 35°C in the embodiment of the present invention.
[0037] Among them, the weight ratio of left-handed polylactic acid (PLLA) to racemic polylactic acid (PDLLA) in the PDLLA / PLLA mixture used in Examples 3, 5 and Comparative Example 3 is 50:50; the weight ratio of PLLA to PDLLA in the PDLLA / PLLA mixture used in Examples 13 to 15 is 60:40; the weight ratio of PLLA to PDLLA in the PDLLA / PLLA mixture used in Examples 16 to 18 and Comparative Example 5 is 65:35.
[0038] The performance testing methods of the embodiments and comparative examples of the present invention are as follows:
[0039] In vitro degradation experiment: It is carried out in a clean bench to ensure a sterile environment. Take 5 interface screws (the samples before degradation are dried to constant weight and then subjected to degradation experiment) injected in each embodiment and comparative example and put them into different high-temperature sterilized glass bottles, add 50mL pH7.4 phosphate buffer (high-temperature sterilization at 121℃, 20min), cover the bottle cap, seal it and place it in a preheated constant temperature incubator. Extract at (37±1)℃, select 0, 8, 16, 24, 32, and 48 weeks for sampling time points, measure the mass of the corresponding interface screws, take another 5 interface screws and implant them into a 20pcf simulated bone block, dry them together with the bone block to constant weight, place them in a high-temperature sterilized glass bottle, add 50ml pH7.4 phosphate buffer saline for in vitro degradation experiment, and measure the corresponding axial pull-out force at the above time points, record the relevant data and convert the mass loss rate and axial pull-out force retention rate;
[0040] Axial pull-out force: Tested in accordance with the method specified in YY / T 1504.
[0041] Table 1
[0042]
[0043] Table 2
[0044]
[0045] Table 3
[0046]
[0047] The inventors unexpectedly discovered through experimental verification that the axial pull-out force of the interface screws prepared in Example 1 and Example 2, which use hydroxyapatite with a smaller particle size as the filler, after 24 weeks of in vitro degradation is only 498N and 506N, which is at the critical point of the maximum load value (500N) during the rehabilitation period of ACL reconstruction verified by clinical studies. However, clinical studies have shown that the normal bone tunnel healing period is about 26 weeks. Therefore, when the interface screws of Example 1 or Example 2 are used for ACL reconstruction, there is a high risk of ligament loosening during the healing period of the patient. The interface screw (Example 1) prepared by using hydroxyapatite powder with a larger particle size as the filler has an axial pull-out force of 798N after 24 weeks of in vitro degradation, and the axial pull-out force retention rate can reach 79.0%. Moreover, after 32 weeks of in vitro degradation, the axial pull-out force is still higher than 500N, which can fully meet the movement needs of patients after normal intrabone ACL reconstruction surgery. However, when the particle size of the filler hydroxyapatite is too large, the interface screws (Example 1) are made of hydroxyapatite powder with a larger particle size as the filler. On the contrary, the axial pull-out force of the surface screw is reduced. For example, in Example 3, hydroxyapatite with a particle size of 11 μm is used as the filler. The axial pull-out force (815 N) of the interface screw prepared therefrom is obviously not as good as the axial pull-out force (1005 N) of the interface screw of Example 5 with a hydroxyapatite particle size of 10 μm, and the attenuation rate of the axial pull-out force after in vitro degradation is faster. After 24 weeks of degradation, the axial pull-out force retention rate of the interface screw of Example 3 is 70.6%, and after 32 weeks of degradation, the axial pull-out force retention rate is only 43.9%, and the axial pull-out force has dropped to 358 N, which is much lower than 540 N of Example 5.
[0048] The inventors have also found through experimental verification that when the dosage ratio of the polylactic acid component to the PLGA component in the interface screw exceeds the range of 1: (4-9), the initial axial pull-out force and the degradation rate are not ideal. For example, in Comparative Example 4, the dosage ratio of the polylactic acid component to the PLGA component is 1:3, and the initial axial pull-out force of the interface screw is only 866N, which is significantly lower than the performance of the interface screws in Examples 7 and 8 in which the dosage ratio of the polylactic acid component to the PLGA component is within the range of 1: (4-9), and the degradation rate is also significantly faster than that in Examples 7 and 8. After 24 weeks of degradation, the axial pull-out force of the interface screw in Comparative Example 4 has dropped to 535N, and after 32 weeks of degradation, the initial axial pull-out force of the interface screw in Comparative Example 4 has dropped to 535N. Its axial pull-out force is lower than 500N, only 412N; compared with Examples 16-18 in which the ratio of the polylactic acid component to the PLGA component is in the range of 1:(4-9), the degradation rate of the interface screw in Comparative Example 5 in which the ratio of the polylactic acid component to the PLGA group is 1:10 is the fastest, and the axial pull-out force retention rate after 32 weeks of degradation is only 41.6%, and the axial pull-out force has dropped to 433N. The interface screws of Comparative Examples 4 and 5 have a high risk of ligament loosening during the ACL reconstruction healing period, especially for ACL injury patients with less than ideal bone quality, the risk of ligament loosening during the ACL reconstruction healing period is even higher.
[0049] Ten interface screws prepared in Example 1 and Comparative Examples 1 and 2 were randomly selected, and initial axial pull-out force tests were performed according to the above axial pull-out force test method. The corresponding initial axial pull-out force data were recorded, and the average value and range were calculated. The test results are shown in Table 4.
[0050] Table 4 Axial pull-out force stability test results
[0051]
[0052] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. An absorbable interference screw, characterized in that: The interface screw is made of a biodegradable polymer composite material consisting of 65 to 80 parts by weight of a degradable high molecular polymer, 5 to 15 parts by weight of polyethylene glycol, 15 to 25 parts by weight of hydroxyapatite and maleic anhydride through an injection molding process, wherein the injection molding temperature is 200 to 240° C., the injection pressure is 200 to 300 bar, and the holding time is 30 to 120 s; the degradable high molecular polymer is a composite of polylactic acid and polylactic acid-glycolic acid copolymer in a weight ratio of 1:(4-9); the hydroxyapatite is hydroxyapatite powder with an average particle size of 800nm-10μm or hydroxyapatite whiskers with a diameter of 50-500nm and an aspect ratio of 10-40; the amount of maleic anhydride in the biodegradable polymer composite material is 1-3% of the total weight of the degradable high molecular polymer, polyethylene glycol and hydroxyapatite; the viscosity-average molecular weight of the polylactic acid is 100,000-200,000, and is selected from at least one of L-polylactic acid, racemic polylactic acid and a blend of L-polylactic acid; the molar content of the monomer lactide in the polylactic acid-glycolic acid copolymer is 50-85%, and the molar content of the monomer glycolide is 15-50%; the viscosity-average molecular weight of the polylactic acid-glycolic acid copolymer is 200,000-600,000.
2. The absorbable interference screw according to claim 1, characterized in that: The viscosity average molecular weight of the polyethylene glycol is 200-10000.
3. The absorbable interference screw according to claim 1, characterized in that: The interface screw is made of a biodegradable polymer composite material consisting of 70 to 75 parts by weight of a degradable high molecular polymer, 7 to 12 parts by weight of polyethylene glycol, and 15 to 20 parts by weight of hydroxyapatite and maleic anhydride through an injection molding process; the polylactic acid in the degradable high molecular polymer is a L-polylactic acid with a viscosity-average molecular weight of 100,000 to 150,000, and the molar ratio of the monomer lactide to the monomer glycolide in the polylactic acid-glycolic acid copolymer is 50:50 or 65:
35.
4. The absorbable interference screw according to claim 3, characterized in that: The weight ratio of polylactic acid to polylactic acid-glycolic acid copolymer in the degradable high molecular polymer is 1:(4-6); the hydroxyapatite is hydroxyapatite powder with an average particle size of 1-5 μm.
5. The absorbable interference screw according to claim 1, characterized in that: The interface screw is made of a biodegradable polymer composite material consisting of 70 to 75 parts by weight of a degradable high molecular polymer, 5 to 10 parts by weight of polyethylene glycol, and 20 to 25 parts by weight of hydroxyapatite and maleic anhydride through an injection molding process; the polylactic acid in the degradable high molecular polymer is a blend of L-polylactic acid and racemic polylactic acid with a viscosity-average molecular weight of 100,000 to 200,000; the molar ratio of the lactide monomer to the glycolide monomer in the polylactic acid-glycolic acid copolymer is 75:25 or 85:
15.
6. The absorbable interference screw according to claim 5, characterized in that: The weight ratio of polylactic acid to polylactic acid-glycolic acid copolymer in the degradable high molecular polymer is 1:(7-9); the hydroxyapatite is a hydroxyapatite whisker with an aspect ratio of 20-40.
7. The absorbable interference screw according to claim 5, characterized in that: The weight ratio of L-polylactic acid to racemic polylactic acid in the blend of L-polylactic acid and racemic polylactic acid is 50-65:35-50.
Citation Information
Patent Citations
Absorbable interference screw for repairing anterior and posterior cruciate ligaments and preparation method of screw
CN102940908A
Hydroxyapatite-modified full-degradable plastic film and preparation method thereof
CN104893220A
Absorbable composite material for interface screw sheath and preparation method thereof
CN111671981A
High-fixing-strength absorbable interface screw
CN111803720A
